A multicenter trial found that endobronchial valve treatment improves lung function, reduces shortness of breath and exercise intolerance, and increases quality of life in patients with severe heterogeneous emphysema. The treatment has been shown to be safe and effective for appropriately selected patients.
A computational model of emphysema has been developed to compare novel and traditional treatments, showing that mechanical forces play a critical role in disease progression. The study suggests that newer lung volume reduction techniques can achieve comparable outcomes as current surgical approaches.
Researchers have developed a lung-targeted gene therapy strategy that may improve treatments for inherited diseases like emphysema. The new approach, which delivers a normal copy of the gene to lung cells, shows promise in reducing disease severity and increasing protein production.
A Japanese retrospective study found that ultralow-dose CT can accurately quantify emphysema disease without excessive radiation. Researchers suggest that this technique could stratify lung cancer risk and reduce radiation exposure in COPD patients.
The minimally invasive implantation of tiny coils improves exercise ability, lung function and quality of life for patients with severe emphysema. Patients who received coils showed a modest improvement in walking distance and lung function compared to those who didn't receive them.
Researchers found that Viking populations' genes developed protection from intestinal parasites, which can lead to emphysema in smokers. The inherited trait was previously unknown.
A new minimally invasive intervention involving lung coil implantation improved exercise capacity in patients with severe emphysema, with significant short-term costs. The treatment also showed long-term benefits, including reduced lung hyperinflation and sustained quality of life improvements.
Researchers identify nanoparticulate carbon black as main culprit in emphysema. The material accumulates in dendritic cells and antigen-presenting cells, causing inflammation and DNA damage. Studies find that size and dose of particles affect toxicity.
A new clinical study published in The Lancet shows that augmentation therapy can preserve lung structure and add years of life for patients with alpha-1 antitrypsin deficiency. The treatment has been found to be effective in slowing the progression of emphysema in severe cases.
A large study found that regular aspirin use was associated with a slower progression of percent emphysema on CT scans over 10 years. Even after adjusting for confounding factors, participants who used aspirin regularly had a significantly slower rate of progression compared to those who did not.
After 10 years of experience with LVRS, the results demonstrate durable benefits in improving airflow, exercise capacity, and dyspnea. Functional improvements are stable for five years, making Surgical LVRS the gold standard for treating advanced emphysema.
Scientists at Helmholtz Zentrum München have identified a new isoform of neutrophil elastase involved in the pathogenesis of pulmonary emphysema. The cleaved form of the enzyme is particularly aggressive and resistant to inhibitors, leading to increased tissue damage.
Research finds a connection between telomere mutations and lung disease, with shorter telomeres indicating a greater chance for bone marrow failure, liver disease, skin disease, and other conditions. The study also highlights the importance of telomere research in understanding lung disease and its potential impact on future generations.
A healthy diet rich in whole grains and polyunsaturated fats is associated with a lower risk of chronic lung disease, according to a study published in The BMJ. The Alternate Healthy Eating Index 2010 was found to be linked to a one-third lower risk of newly diagnosed COPD.
The University of Louisville is conducting a study to evaluate the safety and effectiveness of an investigational device called Zephyr Endobronchial Valve (EBV) for treating emphysema symptoms. The EBV blocks off diseased lung sections, allowing healthier parts to expand.
A new study found that mutations in the telomerase reverse transcriptase (TERT) gene increase the risk of emphysema in smokers. Female smokers with these mutations may be more susceptible to the disease. The researchers also discovered a link between telomere shortening and other health problems, such as osteoporosis and liver disease.
Researchers found that black patients' poorer health at diagnosis, not treatment differences, explains most of the racial disparity in colon cancer survival. Emphysema detected on CT scans is linked to increased mortality among those without airflow obstruction or COPD.
Researchers at MIT developed an algorithm that can accurately determine whether a patient is suffering from emphysema or heart failure based on carbon dioxide readings in their breath. The algorithm achieved an area under the curve of 0.98, outperforming traditional diagnostic methods.
Research on e-cigarettes reveals potential links to asthma and emphysema, as well as a successful quitting aid, but also raises concerns about long-term effects and lack of consensus among doctors. The ERS Congress emphasizes the need for strong regulation to protect vulnerable populations.
A large pooled analysis of seven studies involving over 25,000 individuals found associations between lung cancer and chronic bronchitis, emphysema, and pneumonia. Patients with co-occurring chronic bronchitis, emphysema, and pneumonia had a higher risk of lung cancer.
A study by Duke University researchers found a strong association between improved air quality and declining death rates from emphysema, asthma, and pneumonia in North Carolina. The study analyzed data from 1993-2010 and found that reductions in sulfur dioxide, carbon monoxide, and fine particulates were significantly correlated with l...
Researchers found that PPAR-γ agonists can reverse emphysema development despite continuous exposure to cigarette smoke. Additionally, a compound enhancing glutamate uptake improved ALS symptoms and extended lifespan in mice. Increased autophagy also contributed to BRAF inhibitor resistance in melanoma patients.
Treatment with A1-PI slows the progression of emphysema in patients with Alpha-1 antitrypsin deficiency by preserving lung density. The study showed significant clinical and statistical benefits, confirming the efficacy of augmentation therapy.
A new device, Lung Volume Reduction Coil (LVRC), has shown significant improvements in lung function, ability to exercise, and quality of life for patients with severe emphysema. The device, implanted through a minimally invasive procedure, gathered and compressed diseased lung tissue, allowing healthy tissue to function more efficiently.
Researchers identified a new molecular pathway involved in the growth of tiny air sacs called alveoli crucial for breathing. HGF treatment showed a 17% improvement in air sac size and lung structure, suggesting a potential approach to regrow destroyed air sacs in people with emphysema.
A Norwegian study found that emphysema severity is a strong predictor of all-cause and cardiovascular mortality in ever-smokers with or without COPD. The study also showed that airway wall thickness is associated with respiratory mortality in patients with severe emphysema.
A new study found that smoking history, specifically pack-years, can predict mortality in people with COPD. The researchers analyzed 208 participants and identified age, pack-years, and emphysema area as strong predictors of mortality.
A study led by BUSM researchers has found that the compound Gly-His-Lys (GHK) may halt the progression of emphysema and reverse some of its damage. The study demonstrates potential impact of genomic technologies in identifying new treatments for diseases using existing drugs and compounds.
Researchers found that autologous lung-derived mensenchymal stem cell transplantation improved functional outcomes in sheep with emphysema, with increased blood perfusion and ECM content. The study suggests a practical alternative to conventional stem cell therapy for treating emphysema.
A multicenter trial found that a tiny implanted coil called the Lung Volume Reduction Coil (LVRC) significantly improves pulmonary function, exercise capacity, and quality of life in patients with severe heterogeneous emphysema. The treatment is considered safe and effective, particularly for those with severely hyperinflated lungs.
Researchers at Baylor College of Medicine have identified the specific immune response induced by cigarette smoke as the cause of emphysema. The study found that antigen-presenting cells and genes like interleukin-17 play a crucial role in the development of the disease.
Researchers found that quantitative CT scans can identify patients with greater airway wall thickness and emphysema, who are at higher risk for frequent exacerbations. These findings could lead to individualized, targeted management of COPD disease.
Researchers found that a specific enzyme, iNOS, plays a key role in the development of emphysema. Blocking this enzyme with an inhibitor can prevent disease progression. The study also shows promising results for reversing lung damage using this approach.
A minimally-invasive procedure aimed at reducing lung inflation and shortness of breath in patients with severe emphysema has failed to demonstrate sustained long-term effects. Despite initial improvements, the procedure's durability was lacking, with no significant differences noted between treatment and sham groups after six months.
Researchers used CT scans to identify structural changes in lungs of COPD patients linked to exacerbations. These findings suggest that distinct subgroups of patients may require targeted therapies, independent of spirometry measures.
Researchers found that short telomeres increase emphysema risk after cigarette smoke exposure, suggesting a biological clock mechanism. Telomere length may be an inherited factor contributing to emphysema development.
A gene linked to emphysema is also found to contribute to lung cancer development, with men showing a higher incidence of the disease. The study suggests that PLAGL2 expression could be used as a marker for cells at risk of malignant transformation.
Researchers have made significant breakthroughs in treating various respiratory diseases. A new algorithm-based treatment for pregnant women with asthma has been found to be effective in reducing exacerbations. Additionally, a selective retinoid agonist may slow disease progression in emphysema, while sirolimus shows promise in patient...
A lung protein called EMAPII has been identified as a key player in smoking-related emphysema. An antibody targeting this protein shows promise in reducing cell death and inflammation in mice with emphysema, suggesting potential as a new treatment for the condition.
A new blood test measures destruction of lung air sacs and can detect early emphysema in smokers, potentially preventing disease progression. The test is a low-cost screening tool that could help the 20% of American adults who smoke or are exposed to secondhand smoke understand their risk of developing this progressive lung disease.
Researchers found elevated levels of endothelial microparticles in smokers' blood, even before symptoms appeared. These findings suggest a potential new diagnostic method for early emphysema detection.
Researchers found that interstitial lung disease is associated with reduced total lung capacity and less emphysema in smokers. Smokers with abnormal lung densities are at increased risk for restrictive lung oxygen volume deficits.
Researchers at Johns Hopkins Children's Center discover that the CFTR protein regulates inflammation and cell death in emphysema, potentially leading to new treatments. Decreases in CFTR expression correspond to increased buildup of ceramide, a trigger of inflammation and cell death.
Researchers developed a new test that uses CT scans to measure blood flow in the lungs, identifying smokers most at risk of emphysema. The study found subtle differences in blood flow patterns between smokers with normal lung function and those with early signs of emphysema.
Researchers from Boston University School of Medicine have discovered a gene therapy that can prevent the progression of emphysema by delivering therapeutic genes to lung tissue. The treatment achieved sustained expression of human alpha-1 antitrypsin protein, improving lung compliance and alveolar size in mice with emphysema.
Researchers at Boston University School of Medicine have developed an approach to sustainably express normal human alpha-1 antitrypsin in the mouse lung, reducing emphysema symptoms. This breakthrough could provide a therapeutic approach for overcoming lung diseases caused by single-gene defects.
Researchers discovered that dendritic cells in the lung provoke destructive T-cells that attack elastin, causing lung tissue death and emphysema. The study found a link between systemic inflammation and cardiovascular diseases associated with smoking.
Researchers at the University of Texas Health Science Center at Houston have linked osteopontin to COPD, a potentially novel approach to treatment. Elevated levels of osteopontin were found in people with COPD, suggesting it could serve as both an indicator and therapeutic target.
Researchers at EMBL and University of Heidelberg create fluorescent probe to quantify MMP12 activity in macrophages, allowing study of emphysema development. The test has potential as biomarker for disease evolution and therapeutic intervention monitoring.
A new study found that cumulative exposure to respirable coal mine dust is a significant predictor of emphysema severity in both smokers and never-smokers. The researchers also discovered that emphysema was more severe among miners compared to non-miners, regardless of smoking status.
Patients who underwent lung reduction surgery showed a significant survival benefit compared to medical treatment, with an average time until a 'composite event' of two years. The procedure also improved quality of life for at least five years post-operative period, especially in patients with upper-lobe-predominant emphysema.
Researchers found that non-smokers who reported childhood exposure to ETS were more likely to have CT patterns indicating early emphysema. Childhood ETS exposure may be associated with detectable differences in lung structure and early emphysema later in life, even among non-smokers.
Research reveals that HIV-positive individuals are more susceptible to lung-related problems and experience a swifter decline in lung function compared to their HIV-negative counterparts. The study also found that HIV-positive smokers are at risk of developing early emphysema.
A University of Iowa study found that smoking decreases a key protein in lung cells, leading to cell aging and damage. The team suggests targeting Werner's syndrome protein for developing treatments for smoking-related diseases like emphysema.
Researchers found that activating Nrf2 can prevent emphysema in mice by reducing oxidative stress and improving lung function. The study suggests targeting Nrf2 could be a novel strategy for preventing chronic obstructive pulmonary disease (COPD).
Researchers are conducting a new study to investigate the safety and effectiveness of airway bypass using drug-eluting stents for patients with advanced emphysema or COPD. The trial aims to provide a minimally invasive treatment option for patients who have limited treatment options, such as lung reduction surgery and inhalers.
A University of Michigan study found that cadmium exposure is a critical ingredient in smoking-related emphysema, increasing the risk by up to double. Even low-level exposure through second-hand smoke or other means can also increase lung disease risk.
A clinical trial found that combining nebulized formoterol fumarate with tiotropium significantly improves dyspnea, COPD symptoms, and rescue medication use. The treatment also shows promise in relieving shortness of breath, chest tightness, and nighttime awakenings.
Researchers analyzed medical records of 249 IPF patients and found that current smokers had longer survival times due to milder disease. However, non-smokers had better survival rates, suggesting a possible link between smoking damage and progression of lung disease.
A two-year study involving 321 patients found that endobronchial valves significantly improved measures of lung function and quality of life for emphysema patients. The valves allowed over-distended air sacs to deflate, resulting in increased overall lung function.